Barrett's esophagus, Colon carcinoma, gastrointestinal dysplasia
Conditions
Brief summary
Safety evaluation of immuno-OCT imaging: Number of adverse device-related events (ADE’s) and serious adverse device-related events (SADE’s)., Feasibility of in vivo immuno-OCT imaging and interpretation of the in vivo immuno-OCT results
Detailed description
Validation of the immuno-OCT endoscopy results compared to: Fluorescence seen in FME imaging results; The correlation of ex vivo fluorescent signals to histopathological analysis results; The correlation of in vivo and ex vivo immuno-OCT imaging to histopathological analysis results;
Interventions
DRUGAvastin 25 mg/ml concentrate for solution for infusion.
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety evaluation of immuno-OCT imaging: Number of adverse device-related events (ADE’s) and serious adverse device-related events (SADE’s)., Feasibility of in vivo immuno-OCT imaging and interpretation of the in vivo immuno-OCT results | — |
Secondary
| Measure | Time frame |
|---|---|
| Validation of the immuno-OCT endoscopy results compared to: Fluorescence seen in FME imaging results; The correlation of ex vivo fluorescent signals to histopathological analysis results; The correlation of in vivo and ex vivo immuno-OCT imaging to histopathological analysis results; | — |
Countries
Netherlands
Outcome results
None listed